A partnership offers researchers more biologically representative model systems for understanding disease
Biotechnology companies iXCells Biotechnologies and Rosebud Biosciences have partnered to advance organoid-based models for rare diseases.
In areas such as rare diseases, where predicting human-specific safety and response earlier can significantly impact development timelines and patient outcomes, these integrated systems provide critical insight,” said iXCells CEO Steve Smith.
iXCells is a provider of human cell-based solutions and custom iPSC services, while Rosebud is an innovator in organoid development and complex 3D biology. Combining the two company’s expertise enables the development of a personalised approach for predicting drug safety and informing translational decision-making in rare diseases.
iXCells will integrate Rosebud’s organoid generation and characterisation knowledge into its existing iPSC solutions to allow access to complex 3D human systems that better represent tissue-level biology and simulate therapeutic response.
The combined workflow brings together iXCells’ scalable, modular iPSC platform, iPSCore, with Rosebud’s AI-driven organoid platform, designed to generate scalable, reproducible human tissue data for drug discovery and safety assessment.
“Our partnership with iXCells allows us to make advanced organoid systems more accessible to researchers who need models that better represent human biology,” said Rosebud cofounder and CEO Kitch Wilson. “By combining our complementary strengths, we can support deeper exploration of disease biology and help drive the next generation of therapeutic discovery.”
